Takeda Pharmaceutical Co Ltd
TKD
Company Profile
Business description
Takeda Pharmaceutical is Japan’s largest pharmaceutical company, with revenue of JPY 4.5 trillion in fiscal 2025. The company’s five core therapeutic areas are oncology, gastroenterology, neuroscience, rare diseases, and plasma-derived therapies, which account for more than 80% of revenue. Its geographic footprint is well diversified, with about 50% from the US, 10% from Japan, 25% from Europe, and 15% from Canada.
Contact
1-1, Nihonbashi-Honcho 2-Chome
Chuo-ku
Tokyo103-8668
JPNT: +81 332782306
Sector
Healthcare
Stock type
Defensive
Industry
Drug Manufacturers - Specialty & Generic
Fiscal Year End
31 March 2027
Employees
47,029
Stocks News & Analysis
stocks
Chip stock selloff deepens in Asia, extends to Europe and US
The week’s tech stock rout continues despite strong earnings from TSMC and ASML.
stocks
Downgrade for ASX listed fund manager as redemptions pile on
Persistent outflows erode earnings outlook.
stocks
Tesla stock is down nearly 20% this year. Is it a buy ahead of earnings?
Following the rollout of its first autonomous Cybercab, here’s what we expect from Tesla’s earnings report.
Morningstar Investment Ideas
Markets
Index | Last price | Change | % Change |
|---|---|---|---|
| All Ordinaries | 8,919.10 | 78.70 | 0.89% |
| CAC 40 | 7,934.70 | 61.59 | 0.78% |
| DAX 40 | 25,382.62 | 84.01 | 0.33% |
| Dow JONES (US) | 52,177.69 | 556.21 | 1.08% |
| FTSE 100 | 10,840.35 | 115.49 | 1.08% |
| HKSE | 24,351.54 | 288.82 | 1.20% |
| NASDAQ | 26,713.03 | 20.16 | 0.08% |
| Nikkei 225 | 65,488.71 | 1,062.76 | 1.65% |
| NZX 50 Index | 13,751.45 | 81.35 | -0.59% |
| S&P 500 | 7,744.06 | 25.12 | 0.33% |
| S&P/ASX 200 | 8,785.00 | 65.30 | 0.75% |
| SSE Composite Index | 3,728.66 | 21.19 | 0.57% |